Navigation Links
Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
Date:6/28/2010

to clinically meaningful outcomes for patients.  It is compelling that these data showed a strong correlation between blood glucose variability and C-peptide, particularly because glucose variability was measured with basic finger stick blood glucose testing. Tolerx is seeking additional and more robust data from the ongoing confirmatory Phase 3 DEFEND-2 study in which all subjects will wear a continuous glucose monitor (CGM) at regular intervals," said Aoife Brennan, MD, endocrinologist and Associate Medical Director at Tolerx.  "Our Phase 3 DEFEND-1 and DEFEND-2 clinical trials aim to show that otelixizumab is not only safe and well tolerated, but that it preserves beta cell function."

The Tolerx data presentation at ADA (abstract #700-P), entitled "Lower C-Peptide Secretion Is Associated With Increased Blood Glucose Variability In Adults With New-Onset Type 1 Diabetes: Analysis Of Baseline Data From DEFEND-1," reviewed data from patients within 90 days of diagnosis with new-onset diabetes, monitoring their blood glucose 7 times per day for 7 days prior to the date when the patients began dosing with Tolerx's investigational product candidate, otelixizumab. Two measurements of glucose variability were evaluated for relationship to C-peptide: average daily risk range (ADRR) and mean amplitude of glycemic excursions (MAGE).   With a decrease in each measure of glucose variability, ADRR and MAGE, there was a statistically significant correlation with an increase in C-peptide.  The results demonstrate the relationship between glucose variability and C-peptide, confirming that C-peptide is a robust and important clinical marker for beta cell function and glycemic control.

About the DEFEND-1 Study

DEFEND-1 is a randomized, placebo-controlled Phase 3 study that has achieved its target enrollment of 240 patients, age 12
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
2. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
3. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
4. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
5. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
6. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
7. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
8. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
9. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
10. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
11. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... N.J. , April 28, 2015 As ... Stryker Orthopaedics, is kicking off tournament week by heading ... second consecutive year appearing at the tournament, Stryker continues ... about the importance of joint health and mobility. As ... , Stryker is bringing new features to enhance ...
(Date:4/28/2015)... April 28, 2015   HX360 today ... of the inaugural HX360 Innovation Challenge ... improved patient experience in hospital and health system ... original field of eighty-three entries, with the four ... panel during the HX360 Innovation Challenge program at ...
(Date:4/28/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... I am very excited to announce that we ... clinical trial for oral insulin (ORMD-0801) and the treatment of ... in the coming weeks. This clinical trial will be our largest ... milestone for the company, literally putting us in a different ...
Breaking Medicine Technology:The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 2The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 3The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 4Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 2Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 3Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 2Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 3
... Aug. 2 Cytokine PharmaSciences,Inc. (CPSI) today ... inhibitors showed oral efficacy in animal models. ... it is advancing one of these compounds,into ... or MIF, is linked to many,conditions, including ...
... ARBOR, Mich., Aug. 3 Far more of today,s,heart attack ... clogged heart arteries than even a,decade ago, a new study ... from this urgent treatment,-- which is known to save lives ... it at all, the study shows. And the chance ...
Cached Medicine Technology:Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors 2Many Heart Attack Patients Don't Get Best Emergency Treatment 2Many Heart Attack Patients Don't Get Best Emergency Treatment 3Many Heart Attack Patients Don't Get Best Emergency Treatment 4
(Date:4/28/2015)... Two leaders in patient safety from the ... Hospital Review’s list of 50 Experts Leading the Field ... , director of the Armstrong Institute for Patient ... patient safety and quality at Johns Hopkins Medicine, and ... medical affairs and chief patient safety officer at All ...
(Date:4/28/2015)... 2015 Tools4ever, the market leader ... today that they have been chosen by IT ... Identity and Access Management vendors. IT Central Station ... and Access Management tools by real users in ... analyzed their trends to come up with the ...
(Date:4/28/2015)... New and more complex medicines ... manufacturers, payers, pharmacists and patients. Now Specialty Pharmacy ... partnering with the National Association of Specialty Pharmacy ... to this developing field to better equip pharmacy ... , “This partnership creates a powerful platform for ...
(Date:4/28/2015)... Commack, LI, New York (PRWEB) April 28, 2015 ... Massage Therapy in Commack. 2015 will be the third year ... of attention for the entire week. Hands On is offering ... will be offered. "What better time of the year could ... of Hands On. "All women deserve pampering and this is ...
(Date:4/28/2015)... St. Louis, Missouri (PRWEB) April 28, 2015 ... report that delves into the reality problem Americans ... of the population will need long-term care services as ... will need such care. , In the report, ... from organizations such as the American Health Care Association ...
Breaking Medicine News(10 mins):Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 3Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 4Health News:Tools4ever Chosen as Part of “Top Identity and Access Management Tools - 2015 Edition” 2Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 2Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 3Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 4Health News:Commack Massage Therapy and Wellness Day Spa Dedicates Time To Celebrate Women 2Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2
... 21 Innerscope Research(TM), a revolutionary,biometric media research ... appointment of three executives who will strengthen the,company,s ... The three ... experience,include Geoffrey Gill as Chief Financial Officer and ...
... 2008) How can moss help us to treat ... us about evolution? Can genetic studies of snapdragon populations ... quail teach us about human aging, reproduction, and hereditary diseases? ... , To answer these and other questions in biology, scientists ...
... WASHINGTON, Nov. 21 New inventions in computerized ... cognitive disabilities lead fuller,lives, said Jeff Zimman, Chairman ... annual Technology Innovators Conference in Washington,DC, a meeting ... to,promote innovation to assist people with disabilities. , ...
... , , FRIDAY, Nov. 21 (HealthDay News) -- The season of ... new research suggests. , Babies born in autumn -- about four ... a 30 percent increased risk of asthma compared to babies born ... first December issue of the American Journal of Respiratory and ...
... patients with cardiovascular disease are not given adequate drug therapy. ... current edition of Deutsches rzteblatt International ( Dtsch ... present the German results of this prospective, one-year survey. , ... enrolled 5594 patients in all, of whom 89.2% suffered from ...
... Texas, Nov. 21 Huntsman,Corporation (NYSE: HUN ) ... one of four Americans chosen by the American Cancer Society ... Given annually, the,award is reserved for those who have made ... Noting that Mr. Huntsman and his wife ...
Cached Medicine News:Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2Health News:A new world of research possibilities with 'Emerging Model Organisms' 2Health News:New Applications for Cognitive Training 2Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3Health News:Jon M. Huntsman Receives American Cancer Society Medal of Honor 2
Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels....
... assay for the detection of the APC ... to activated protein C (APC). The test ... the anticoagulant function in vivo and provides ... inherited and acquired APC resistance. Detects the ...
Inquire...
... This remarkable anti-reflux valve is ... housing which prevents the valve ... when in sitting or reclining ... self-cleaning and interference free ensuring ...
Medicine Products: